Concurrent radiochemotherapy in advanced breast cancer

A. G. Meek, S. E. Order, M. D. Abeloff, David S Ettinger, R. Robinson Baker, E. Baral

Research output: Contribution to journalArticle

Abstract

An initial trial to determine whether the theoretical advantage of concurrent systemic chemotherapeutic protection and local control (by radiation) could be achieved has been applied to 16 patients with breast cancer (Stage 3 and 4). CMFP/CMF combination chemotherapy has been administered with external irradiation (5000 rad breast, 4000-4400 rad nodes). External irradiation was successfully accomplished with tangential fields to avoid combined modality esophagitis while achieving internal mammary node irradiation. Six patients subsequently received Iridium-192 interstitial implantation. Six patients treated preoperatively (4000 rad, breast) were able to have modified mastectomy within 3-6 weeks of completing radiation therapy without graft requirement or undue morbidity. Acute reactions during therapy included some amplification of epidermitis and myelosuppression. Prolongation of the radiation treatment course occurred in two patients and delay in chemotherapy cycles in four patients. In two patients, the leukocyte count nadir was below 1000 and one was hospitalized with fever. The majority of the patients achieved 75% of the designed chemotherapeutic doses in the ensuing year. Many of the patients with advanced disease were administered an Adriamycin-containing regimen upon completion of the radiation therapy. The current results suggest that it would be feasible to initiate a randomized prospective study using these techniques to compare sequential and concomitant chemo-radiation therapy in primary breast cancer to determine whether there is significant advantage in local control and duration of NED survival in either of the treatment regimens.

Original languageEnglish (US)
Pages (from-to)1001-1006
Number of pages6
JournalCancer
Volume51
Issue number6
DOIs
StatePublished - 1983

Fingerprint

Chemoradiotherapy
Breast Neoplasms
Breast
Radiotherapy
Radiation
Modified Radical Mastectomy
Iridium
Esophagitis
Combination Drug Therapy
Leukocyte Count
Doxorubicin
Fever
Therapeutics
Prospective Studies
Morbidity
Transplants
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Concurrent radiochemotherapy in advanced breast cancer. / Meek, A. G.; Order, S. E.; Abeloff, M. D.; Ettinger, David S; Baker, R. Robinson; Baral, E.

In: Cancer, Vol. 51, No. 6, 1983, p. 1001-1006.

Research output: Contribution to journalArticle

Meek, A. G. ; Order, S. E. ; Abeloff, M. D. ; Ettinger, David S ; Baker, R. Robinson ; Baral, E. / Concurrent radiochemotherapy in advanced breast cancer. In: Cancer. 1983 ; Vol. 51, No. 6. pp. 1001-1006.
@article{83ac5c805ae74dec96831ef2e5edc326,
title = "Concurrent radiochemotherapy in advanced breast cancer",
abstract = "An initial trial to determine whether the theoretical advantage of concurrent systemic chemotherapeutic protection and local control (by radiation) could be achieved has been applied to 16 patients with breast cancer (Stage 3 and 4). CMFP/CMF combination chemotherapy has been administered with external irradiation (5000 rad breast, 4000-4400 rad nodes). External irradiation was successfully accomplished with tangential fields to avoid combined modality esophagitis while achieving internal mammary node irradiation. Six patients subsequently received Iridium-192 interstitial implantation. Six patients treated preoperatively (4000 rad, breast) were able to have modified mastectomy within 3-6 weeks of completing radiation therapy without graft requirement or undue morbidity. Acute reactions during therapy included some amplification of epidermitis and myelosuppression. Prolongation of the radiation treatment course occurred in two patients and delay in chemotherapy cycles in four patients. In two patients, the leukocyte count nadir was below 1000 and one was hospitalized with fever. The majority of the patients achieved 75{\%} of the designed chemotherapeutic doses in the ensuing year. Many of the patients with advanced disease were administered an Adriamycin-containing regimen upon completion of the radiation therapy. The current results suggest that it would be feasible to initiate a randomized prospective study using these techniques to compare sequential and concomitant chemo-radiation therapy in primary breast cancer to determine whether there is significant advantage in local control and duration of NED survival in either of the treatment regimens.",
author = "Meek, {A. G.} and Order, {S. E.} and Abeloff, {M. D.} and Ettinger, {David S} and Baker, {R. Robinson} and E. Baral",
year = "1983",
doi = "10.1002/1097-0142(19830315)51:6<1001::AID-CNCR2820510606>3.0.CO;2-9",
language = "English (US)",
volume = "51",
pages = "1001--1006",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Concurrent radiochemotherapy in advanced breast cancer

AU - Meek, A. G.

AU - Order, S. E.

AU - Abeloff, M. D.

AU - Ettinger, David S

AU - Baker, R. Robinson

AU - Baral, E.

PY - 1983

Y1 - 1983

N2 - An initial trial to determine whether the theoretical advantage of concurrent systemic chemotherapeutic protection and local control (by radiation) could be achieved has been applied to 16 patients with breast cancer (Stage 3 and 4). CMFP/CMF combination chemotherapy has been administered with external irradiation (5000 rad breast, 4000-4400 rad nodes). External irradiation was successfully accomplished with tangential fields to avoid combined modality esophagitis while achieving internal mammary node irradiation. Six patients subsequently received Iridium-192 interstitial implantation. Six patients treated preoperatively (4000 rad, breast) were able to have modified mastectomy within 3-6 weeks of completing radiation therapy without graft requirement or undue morbidity. Acute reactions during therapy included some amplification of epidermitis and myelosuppression. Prolongation of the radiation treatment course occurred in two patients and delay in chemotherapy cycles in four patients. In two patients, the leukocyte count nadir was below 1000 and one was hospitalized with fever. The majority of the patients achieved 75% of the designed chemotherapeutic doses in the ensuing year. Many of the patients with advanced disease were administered an Adriamycin-containing regimen upon completion of the radiation therapy. The current results suggest that it would be feasible to initiate a randomized prospective study using these techniques to compare sequential and concomitant chemo-radiation therapy in primary breast cancer to determine whether there is significant advantage in local control and duration of NED survival in either of the treatment regimens.

AB - An initial trial to determine whether the theoretical advantage of concurrent systemic chemotherapeutic protection and local control (by radiation) could be achieved has been applied to 16 patients with breast cancer (Stage 3 and 4). CMFP/CMF combination chemotherapy has been administered with external irradiation (5000 rad breast, 4000-4400 rad nodes). External irradiation was successfully accomplished with tangential fields to avoid combined modality esophagitis while achieving internal mammary node irradiation. Six patients subsequently received Iridium-192 interstitial implantation. Six patients treated preoperatively (4000 rad, breast) were able to have modified mastectomy within 3-6 weeks of completing radiation therapy without graft requirement or undue morbidity. Acute reactions during therapy included some amplification of epidermitis and myelosuppression. Prolongation of the radiation treatment course occurred in two patients and delay in chemotherapy cycles in four patients. In two patients, the leukocyte count nadir was below 1000 and one was hospitalized with fever. The majority of the patients achieved 75% of the designed chemotherapeutic doses in the ensuing year. Many of the patients with advanced disease were administered an Adriamycin-containing regimen upon completion of the radiation therapy. The current results suggest that it would be feasible to initiate a randomized prospective study using these techniques to compare sequential and concomitant chemo-radiation therapy in primary breast cancer to determine whether there is significant advantage in local control and duration of NED survival in either of the treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0020656048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020656048&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19830315)51:6<1001::AID-CNCR2820510606>3.0.CO;2-9

DO - 10.1002/1097-0142(19830315)51:6<1001::AID-CNCR2820510606>3.0.CO;2-9

M3 - Article

C2 - 6821863

AN - SCOPUS:0020656048

VL - 51

SP - 1001

EP - 1006

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -